Synaptic Plasticity is Altered by Treatment with Pharmacological Levels of Retinoic Acid Acting Nongenomically However Endogenous Retinoic Acid has not been shown to have Nongenomic Activity.
Synaptic Plasticity is Altered by Treatment with Pharmacological Levels of Retinoic Acid Acting Nongenomically However Endogenous Retinoic Acid has not been shown to have Nongenomic Activity.
复制标题
DOI：
--
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Duester G
中科院分区：
文献类型：
--
作者：
Duester G
视黄酸（Retinoic acid， RA）是维生素A的活性形式，作为核RA受体的配体，直接结合基因组控制区来调节基因表达。然而，一些研究表明RA可能在核外具有非基因组效应，特别是在突触可塑性方面。最近的研究结果表明，用药理学水平的RA治疗可以改变突触的可塑性，这可能有助于治疗神经系统疾病。然而，这些结果和其他人报道的结果并没有表明内源性RA通常是突触可塑性（或任何其他非基因组效应）所必需的，因为没有关于在成人大脑中去除内源性RA的遗传功能丧失研究的报道。这意味着类风湿性关节炎的药理学水平会导致非基因组效应，其中一些可能有助于治疗某些疾病，但在其他情况下，这可能会导致不必要的副作用。
Retinoic acid (RA) is the active form of vitamin A that functions as a ligand for nuclear RA receptors that directly bind genomic control regions to regulate gene expression. However, some studies have suggested that RA may have nongenomic effects outside of the nucleus, particularly with regard to synaptic plasticity. Recent results demonstrate that treatment with pharmacological levels of RA can alter synaptic plasticity which may be useful to treat neurological diseases. However, these results and those reported by others have not shown that endogenous RA is normally required for synaptic plasticity (or any other nongenomic effect) as there are no reports of genetic loss of function studies that remove endogenous RA in adult brain. The implication is that pharmacological levels of RA result in nongenomic effects, some of which may be helpful to treat certain diseases but in other cases this may cause unwanted side effects.